Loading...
Immune RECIST Criteria and Symptomatic Pseudoprogression in Non-small Cell Lung Cancer Patients Treated with Immunotherapy
BACKGROUND: Uncommon response during immunotherapy is a new challenging issue in oncology practice. Recently, new criteria for evaluation of response to immunotherapy immune response evaluation criteria in solid tumors (iRECIST) were accepted. According to iRECIST, worsening of performance status (P...
Na minha lista:
| Udgivet i: | Radiol Oncol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Sciendo
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6287173/ https://ncbi.nlm.nih.gov/pubmed/30367809 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2478/raon-2018-0037 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|